English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis ( AS ), with response rates sustained for up to 5 years. Here, we report end‐of‐study 3‐year efficacy and safety results of secukinumab 150 and 300 mg from the  MEASURE  3 study.    Methods  A total of 226 patients was randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous (s.c.) secukinumab 300/150 mg every 4 weeks or a matched placebo. At week 16, placebo patients were re‐randomized to s.c. secukinumab 300/150 mg. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 300/150 mg). Outcome measures at week 156 included Assessment of Spondyloarthritis International Society ( ASAS ) 20/40, Bath Ankylosing Spondylitis Disease Activity Index,  ASAS  partial remission ( PR ),  ASAS  5/6, and Ankylosing Spondylitis Disease Activity Score–C‐reactive protein inactive disease.    Results  The retention rates from weeks 16 to 156 were 80.5% and 80.9% in secukinumab 300 and 150 mg, respectively.  ASAS  20/40 response rates at week 156 were 75.0%/56.5% and 68.2%/47.7% for secukinumab 300 and 150 mg, respectively. At week 156, response rates on more stringent clinical end points (eg,  ASAS  40,  ASAS ‐ PR ) were higher with the 300‐mg dose, particularly in tumor necrosis factor ( TNF )–inadequate responder ( IR ) patients. No new safety findings were observed.    Conclusion  Secukinumab (300 and 150 mg) provided sustained improvements through 3 years in the signs and symptoms of active  AS . Improvements with secukinumab 300 mg were numerically higher compared with the 150‐mg dose for some higher hurdle end points and in  TNF ‐ IR  patients. The safety profile of secukinumab was consistent with previous reports.

acr open rheumatology

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3  MEASURE  3 Study